Raised transaminases (hepatocellular injury)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
ALT or AST < 5 × ULN, without severity signs
Fasting laboratory tests
- AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
- Serum albumin
- PT
- FBC with platelets
- Hepatitis B serology (HBsAg, anti-HBc and anti-HBs antibodies)
- Hepatitis C serology (HCV RNA if positive)
- Serum ferritin
- Transferrin saturation (same sample)
- Fasting plasma glucose
- Lipid profile
- Tissue autoantibodies on triple substrate (antinuclear, anti-smooth muscle, anti-LKM1, antimitochondrial)if needednon-French guidelineImmediately according to the BSG; for the ACG, mainly if there is an associated autoimmune disease (thyroiditis, IBD, rheumatoid arthritis, etc.) or persistent cytolysis [1,2].
- IgGif needednon-French guidelineImmediately according to the BSG; for the ACG, mainly if there is an associated autoimmune disease (thyroiditis, IBD, rheumatoid arthritis, etc.) or persistent cytolysis [1,2].
- Abdominal ultrasound (not a laboratory test)
Do not order
- Repeating the same liver tests "to see" without an aetiological work-up: 84% of abnormalities persist at 1 month and half of abnormal liver tests are never investigated [1]
- Looking for the C282Y mutation (HFE) straight away: management only if transferrin saturation exceeds 45% on two samples, or in a first-degree relative of a homozygote [3]
ALT or AST between 5 and 15 × ULN (without severity signs)
Rapid laboratory tests (within the next few days)
- AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
- Serum albumin
- PT
- FBC with platelets
- Anti-HAV IgM
- Hepatitis B serology (HBsAg, anti-HBc and anti-HBs antibodies; anti-HBc IgM added by the laboratory if HBsAg positive)
- Hepatitis C serology (HCV RNA if positive)
- Tissue autoantibodies on triple substrate (antinuclear, anti-smooth muscle, anti-LKM1, antimitochondrial)
- IgG
- Caeruloplasmin
- Anti-HEV IgM
- EBV serologyif needednon-French guidelineAcute hepatitis with no cause found by A, B, C (and E) serologies; mononucleosis-like syndrome; ALT > 1 000 IU/L [1,2].
- CMV serologyif needednon-French guidelineAcute hepatitis with no cause found by A, B, C (and E) serologies; mononucleosis-like syndrome; ALT > 1 000 IU/L [1,2].
- CK (if intense exercise, trauma or muscle pain)if needednon-French guidelineAST-predominant, intense physical exertion, trauma or muscle signs: exclude a muscular origin (rhabdomyolysis) [2].
- Abdominal ultrasound (not a laboratory test)
> 15 × ULN, or low prothrombin time, jaundice, confusion: emergency
- No tests in the community: refer the same day to the emergency department or the hepatologist.
- Warning signs: low PT, encephalopathy (confusion, asterixis), unexplained jaundice, possible paracetamol intake.
Second-line tests (persistent hepatocellular injury, no cause found)
Laboratory tests
- AST
- ALT
- Alpha-1-antitrypsin
- IgA anti-tissue transglutaminase antibodies (tTG-IgA)
- Total IgA
- TSH
- Creatine kinase (CK)
- Caeruloplasmin (before age 40)if needednon-French guidelineYoung patient: between 3 and 40 years according to the BSG, under 55 years according to the ACG [1,2].
- Tissue autoantibodies on triple substrate and IgG (if not already done)if needednon-French guidelineNot done at the first tests: they are part of the BSG basic work-up and of the ACG work-up for persistent abnormalities [1,2].
- HEV RNA in blood (immunocompromised patient)if neededImmunocompromised patient (solid organ or stem cell transplant recipient, HIV, haematological malignancy) with persistent cytolysis: in these patients hepatitis E can become chronic [7]; HAS places HEV RNA testing in the diagnosis of acute or chronic infection in the immunocompromised [7]; the NABM limits it to these situations and to severe acute hepatitis in the immunocompetent [3].
Sources (8)
- Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests (British Society of Gastroenterology). Gut. 2018;67(1):6-19.
- Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 4124 (ARN du VHC), 4500-4501 (hépatite B), 8000 (mutation C282Y), 0350, 4502, 4503, 1807, 1809.
- Association française pour l'étude du foie (AFEF). Recommandations pour le diagnostic et le suivi non-invasif des maladies chroniques du foie (coord. V. de Lédinghen). Juillet 2020. Chapitre 4 : stéatopathie métabolique (J. Boursier).
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17(4):374-444 (publication simultanée : J Hepatol. 2024;81(3):492-542, PMID 38851997).
- Langan RC, Hines-Smith KA. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 2024;110(6):585-591.
- Haute Autorité de santé. Actualisation des actes de biologie médicale relatifs au diagnostic et au suivi de l'hépatite E. Rapport d'évaluation technologique (argumentaire), juillet 2017.
- Goenner S, Corriat-Boutron A, Pelletier G, Legrand A, Buffet C. Macroaspartate aminotransférase. Étude de 5 cas et revue de la littérature. Gastroenterol Clin Biol. 1998;22(5):549-53.